AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Thursday, October, 3rd. The medical instruments supplier reported $0.08 EPS for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.04. The medical instruments supplier earned $66 million during the quarter, compared to the consensus estimate of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. The firm's revenue was up 3.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.16 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 Wall Street analysts have issued 12-month price objectives for AngioDynamics' shares. Their forecasts range from $21.00 to $23.00. On average, they expect AngioDynamics' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Press coverage about ANGO stock has trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AngioDynamics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for AngioDynamics.

AngioDynamics saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 1,130,000 shares, a decline of 17.5% from the August 30th total of 1,370,000 shares. Based on an average daily trading volume, of 235,900 shares, the days-to-cover ratio is presently 4.8 days. Approximately 3.1% of the company's stock are short sold. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), General Electric (GE), Intel (INTC), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), DIGITAL RLTY TR/SH (DLR), Hanesbrands (HBI), Kimco Realty (KIM) and Regions Financial (RF).

AngioDynamics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Foundry Partners LLC (0.65%), State of New Jersey Common Pension Fund D (0.40%), Rhumbline Advisers (0.32%) and Envestnet Asset Management Inc. (0.17%). Company insiders that own AngioDynamics stock include Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Foundry Partners LLC, Brinker Capital Inc. and Strs Ohio. Company insiders that have sold AngioDynamics company stock in the last year include Kevin J Gould and Michael Greiner. View Insider Buying and Selling for AngioDynamics.

ANGO stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Assenagon Asset Management S.A., Meeder Asset Management Inc., State of Alaska Department of Revenue, Rhumbline Advisers, Pacer Advisors Inc., Nisa Investment Advisors LLC and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $14.33.

AngioDynamics has a market capitalization of $539.09 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]